Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients

Kidney International

Volumn 61, Issue 2, 2002, Pages 609-614

  Mallamaci, Francesca ^a,b,c,d   Zoccali, Carmine ^a,b,c,d   Tripepi, Giovanni ^a,b,c,d   Fermo, Isabella ^a,b,c,d   Benedetto, Francesco A ^a,b,c,d   Cataliotti, Alessandro ^a,b,c,d   Bellanuova, Ignazio ^a,b,c,d   Malatino, Lorenzo Salvatore ^a,b,c,d   Soldarini, Armando ^a,b,c,d  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Servizio di Cardiologia Ospedale 'E Morelli'   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Arteriovenous disease; Blood pressure; Cardiovascular risk; Dialysis; Homocysteine; Mortality study; Thrombosis

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL;

EID: 0036153990     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00144.x     Document Type: Article

References (36)

1. Report on management of renal failure in Europe XXII, 1991
2. Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start?
3. Sulphr containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide
4. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients
5. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
6. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
7. Plasma homocysteine in renal failure
8. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
9. Net uptake of plasma homocysteine by the rat kidney in vivo
10. Elimination of homocysteine from plasma in subjects with end stage renal failure
11. Folate status is the major determinant of fasting plasma homocysteine in hemodialysis patients
12. Membrane protein damage and methylation reactions in chronic renal failure
13. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
14. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
15. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
16. Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients
17. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients
18. Homocysteine and vascular access complications in haemodialysis patients: Insights into a complex metabolic relationship
19. Influence of biochemical alterations on arterial stiffness in patients with end stage renal disease
20. Association between plasma homocysteine concentrations and cardiac hypertrophy in end stage renal disease
21. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients
22. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
23. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
24. Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease
25. High-performance liquid chromatographic method for measuring total plasma homocysteine levels
26. Radioenzymatic assay for direct measurement of plasma pyridoxal 5′-phosphate
27. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients
28. C reactive protein and atherosclerosis in dialysis patients
29. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
30. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
31. Hematocrit level and associated mortality in hemodialysis patients
32. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study
33. Cardiac Troponin T predicts mortality in patients with end stage renal disease
34. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
35. The effect of MTHFR genotypes and hyperhomocysteinemia on patients and graft survival in kidney transplant recipients
36. Treatment with different doses of folic acid in hemodialysis patients: Effects on folate distribution and aminothiol concentrations